APA (7th ed.) Citation

Irie, H., Ito, K., Kataoka, Y., Fujioka, Y., Oguchi, K., Shimamura, T., . . . Iwasawa, Y. (2016). 58 - TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent and sustained inhibition against the HER2–HER3 signaling while sparing EGFR activity, leading to a large therapeutic window. European Journal of Cancer, 69, S26. https://doi.org/10.1016/S0959-8049(16)32658-2

Chicago Style (17th ed.) Citation

Irie, H., et al. "58 - TPC-107, a Next Generation, HER2 Selective Covalent Inhibitor Demonstrates Potent and Sustained Inhibition Against the HER2–HER3 Signaling While Sparing EGFR Activity, Leading to a Large Therapeutic Window." European Journal of Cancer 69 (2016): S26. https://doi.org/10.1016/S0959-8049(16)32658-2.

MLA (9th ed.) Citation

Irie, H., et al. "58 - TPC-107, a Next Generation, HER2 Selective Covalent Inhibitor Demonstrates Potent and Sustained Inhibition Against the HER2–HER3 Signaling While Sparing EGFR Activity, Leading to a Large Therapeutic Window." European Journal of Cancer, vol. 69, 2016, p. S26, https://doi.org/10.1016/S0959-8049(16)32658-2.